Characteristics and management of patients with immune checkpoint inhibitor-mediated neurotoxicities

Takeaway

  • Clinicians prescribing immune checkpoint inhibitor (ICI) therapy, used in several cancer typess, should be vigilant of treatment-related neurotoxicities, as early diagnosis and treatment can help prevent morbidity and mortality.

Why this matters

  • ICI-associated neurotoxicities are uncommon and can involve the CNS, peripheral nervous and neuroendocrine systems. If untreated, these neurotoxicities can be associated with significant morbidity and mortality.

  • Currently, the pathogenesis of ICI-associated neurotoxicities is not established, and clinical management and outcomes have only been derived from case reports/case series.